Abstract
Pharmacotherapy for abdominal aortic aneurysm (AAA) can be useful for prevention, especially in people at higher risk, for slowing down AAA progression, as well as for post-surgery adjuvant treatment. Our review focuses on novel pharmacotherapy approaches targeted towards slowing down progression of AAA, known also as secondary prevention therapy. Guidelines for AAA are not specific to slow down the expansion rate of an abdominal aortic aneurysm, and therefore no medical therapy is recommended. New ideas are urgently needed to develop a novel medical therapy. We are hopeful that in the future, pharmacologic treatment will play a key role in the prevention and treatment of AAA.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference72 articles.
1. Abdominal aortic aneurysms;Sakalihasan;Nat. Rev. Dis. Prim.,2018
2. Recent advances in pharmacotherapy development for abdominal aortic aneurysm;Yoshimura;Int. J. Vasc. Med.,2012
3. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm;Yoshimura;Curr. Drug Targets,2018
4. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase;Yoshimura;Nat. Med.,2005
5. Yoshimura, K., Aoki, H., Teruyama, C., Iijima, M., Tsutsumi, H., Kuroda, S., and Kamano, H. (2020). A Novel Hybrid Drug Delivery System for Treatment of Aortic Aneurysms. Int. J. Mol. Sci., 21.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献